Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Elranatamab May Represent Next Breakthrough in Relapsed/Refractory Myeloma

August 17th 2021

Alexander M. Lesokhin, MD, discusses the promise of elranatamab in the treatment of patients with relapsed/refractory multiple myeloma, the objective of MagnetisMM-3, and other emerging approaches that are generating excitement in the paradigm.

Momelotinib Improves Transfusion Independence Rates Vs Ruxolitinib in Anemic, JAK Inhibitor–Naïve Myelofibrosis

August 12th 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.

Neoadjuvant Stereotactic Radiation Shows Early Safety, Feasibility in RCC Inferior Vena Cava Tumor Thrombus

August 12th 2021

Neoadjuvant stereotactic radiation followed by radical nephrectomy and thrombectomy is a safe and feasible treatment option for patients with renal cell carcinoma and inferior vena cava tumor thrombus.

CheckMate-73L to Examine Nivolumab/Ipilimumab Following Nivolumab/Chemoradiation in NSCLC

August 11th 2021

Nagla F. Abdel Karim, MD, discusses the ongoing CheckMate-73L trial in patients with stage III non–small cell lung cancer, the potential impact of the research on the paradigm, and future areas of exploration.

GEN-1 Plus Neoadjuvant Chemo Appears Active, Safe in Advanced Ovarian Cancer

August 8th 2021

The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.

Overcoming Treatment Barriers With Adjuvant Durvalumab in Unresectable Stage III NSCLC

August 4th 2021

Benjamin H. Kann, MD, discusses the significance of the PACIFIC trial in patients with stage III NSCLC, existing barriers to treatment, and shared strategies to overcome common challenges faced in clinical practice.

CD38 Expression Linked With Poor OS in Prostate Cancer

August 3rd 2021

The role of CD38 within prostate cancer progression must be further explored, along with CD38-targeting in patients with high-risk disease.

Pevonedistat Shows Promising Partner Potential for HMAs in Higher-Risk MDS

August 3rd 2021

Joshua F. Zeidner, MD, discusses the role that HMAs have played in the MDS treatment landscape and shared data reported with promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

August 1st 2021

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

New Tool Improves Accurate Excision of Previously Positive Axillary Lymph Nodes After Neoadjuvant Chemo in Breast Cancer

July 28th 2021

Leslie L. Montgomery, MD, and Tara M. Balija, MD, discuss the benefits of a novel reflector device in patients with breast cancer, its efficacy in identifying clipped axillary lymph nodes, and the potential future use of this device in other cancer types.

Multimodality Approaches Improve Outcomes in Marginally-Inoperable Soft Tissue Sarcoma

July 26th 2021

A multimodality approach to treatment, which included sequential chemotherapy and radiation therapy followed by surgery, resulted in successful resection for most patients with marginally inoperable soft tissue sarcomas.

Blood-based Test Shows Promising Accuracy in Detecting Cancer-Signal Across Multiple Tumor Types

July 23rd 2021

Multicancer early detection tests yielded high specificity and accuracy in predicting cancer signal origin and identified cancer signals in multiple tumor types.

Brain Metastases Occur in Significant Percentage of Advanced RCC, Underscoring Potential Role for Routine Brain Imaging

July 23rd 2021

Brain imaging should be considered for patients with advanced or metastatic renal cell carcinoma who have a high metastatic burden and who have progressed after treatment with first-line therapies.

Nuanced Approaches Needed to Adequately Manage Symptoms, Guide Care in Myelofibrosis

July 23rd 2021

Raajit K. Rampal, MD, PhD, discusses symptom management in patients with myelofibrosis, defining disease progression, and key considerations for starting or delaying treatment.

Venetoclax Plus Lenalidomide/Rituximab Elicits High Response Rates in Newly Diagnosed MCL

July 22nd 2021

The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.

New Tool Could Help Predict Outcomes with 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer

July 22nd 2021

A new prognostic tool, the nomogram, has demonstrated the ability to predict outcomes following treatment with lutetium-177 prostate-specific membrane antigen in patients with metastatic castration-resistant prostate cancer, and could potentially be used to inform future trial designs and clinical decisions.

Completion of Treatment Within 38 Weeks of Breast Cancer Diagnosis Linked With Improved OS

July 22nd 2021

Completion of treatment options such as surgery, chemotherapy, and radiation within 38 weeks from a diagnosis with breast cancer was associated with improved survival in this population.

Ficlatuzumab Plus Chemotherapy Produces Promising Preliminary Clinical Activity in High-Risk AML

July 21st 2021

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.

Nivolumab Plus Chemo or Ipilimumab Represent Potential First-Line Standards in Advanced ESCC

July 21st 2021

Nivolumab plus chemotherapy or ipilimumab showcased superior overall survival over chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma.

Pamrevlumab Plus Chemo Under Exploration in Novel Pancreatic Cancer Trial Platform

July 20th 2021

A new experimental treatment arm examining pamrevlumab in combination with gemcitabine and nab-paclitaxel as a first- or second-line treatment for patients with metastatic pancreatic cancer has been added to the novel clinical trial platform Precision Promise, which is being conducted by the Pancreatic Cancer Action Network.